MigraineMind research summary

Effect of chronic migraine treatment on functional seizure frequency: An exploratory study.

Seizure | 2026

Clinical trial
AuthorsKyrgyzbay G, Kasenova A, Ornello R, Alzhanova D, Utebekov Z
JournalSeizure
Publication year2026
PubMed ID42401138

Summary

Chronic migraine often coexists with functional seizures, which are challenging to manage. This study aimed to see if migraine treatment impacts seizure frequency in patients. Researchers selected patients suffering from chronic migraine and functional seizures. Initially, these patients underwent a three-month observation without treatment. Afterward, they received two injections of botulinum toxin type A. The first injection occurred in the fourth month, while the second followed in the seventh month. Researchers analyzed patient records over nine months, focusing on headache days and seizure counts. Results showed that treatment reduced headache days by 49% and seizure counts by 81%. Additionally, the treatment decreased headache days by about 8.6 days during the observation period. The findings suggest migraine treatment might help reduce seizure frequency in these patients. More research is needed to explore the link between migraines and functional seizures. Clinical relevance: This study highlights that treating migraine may significantly reduce functional seizure frequency.

Key Learning Points

  • Chronic migraine and functional seizures often occur together, making management difficult for patients and clinicians.
  • Migraine treatment using botulinum toxin type A significantly reduced headache days by 49%.
  • Patients experienced an 81% reduction in seizure counts after receiving migraine treatment.
  • During the initial observation period, patients had about 8.6 fewer headache days on average.
  • Further research is necessary to better understand the relationship between migraines and functional seizures.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.